1350322-55-2

Upstream product

• 1350322-57-4 3-chloro-2-dimethoxymethyl-4-fluorophenol 
• 1895-39-2 sodium chlorodifluoroacetate 
• 261762-39-4 2-chloro-3,6-difluorobenzaldehyde 
• 1263378-00-2 2-chloro-3-fluoro-6-hydroxy-benzaldehyde 
• 1263378-40-0 2-chloro-3-fluoro-6-methoxy-benzaldehyde 
• 202925-07-3 2-chloro-1-fluoro-4-methoxybenzene 

Downstream Products

• 1350322-56-3 2-Chloro-6-difluoromethoxy-3-fluorobenzaldehyde 
• 1350324-73-0 5-bromo-3-{[2-chloro-6-(difluoromethoxy)-3-fluorophenyl](methoxy)methyl}(2-2H)-1H-pyrrolo[2,3-b]pyridine 
• 1350324-72-9 [5-bromo(2-2H)-1H-pyrrolo[2,3-b]pyridin-3-yl][2-chloro-6-(difluoromethoxy)-3-fluorophenyl]methanol 
• 1350324-71-8 5-bromo-3-{1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}(2-2H)-1H-pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

FUSED BICYCLIC KINASE INHIBITORS

Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.